Context Therapeutics (CNTX) Stock Price, News & Analysis

Company Overview

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.96 to $1.11
• 50-Day Range: $1.02 to $2.35
• 52-Week Range: $0.89 to $2.75
• Volume: 339,733 shs
• Average Volume: 299,858 shs
• Market Capitalization: $76.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.80
• Consensus Rating: Buy

Context Therapeutics Stock Analysis - MarketRank™

Context Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 438th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Context Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Context Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Context Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Context Therapeutics is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Context Therapeutics has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.36% of the float of Context Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Context Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Context Therapeutics has recently decreased by 8.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Context Therapeutics does not currently pay a dividend.

Dividend Growth

Context Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.36% of the float of Context Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Context Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Context Therapeutics has recently decreased by 8.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Context Therapeutics has a news sentiment score of 1.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Context Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Context Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.04% of the stock of Context Therapeutics is held by insiders.

Percentage Held by Institutions

Only 14.03% of the stock of Context Therapeutics is held by institutions.

CNTX Stock Analysis - Frequently Asked Questions

How have CNTX shares performed this year?

Context Therapeutics' stock was trading at $1.13 at the beginning of the year. Since then, CNTX shares have decreased by 9.7% and is now trading at $1.02.
View the best growth stocks for 2024 here.

How were Context Therapeutics' earnings last quarter?

Context Therapeutics Inc. (NASDAQ:CNTX) announced its earnings results on Wednesday, November, 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.11.

When did Context Therapeutics IPO?

Context Therapeutics (CNTX) raised $25 million in an initial public offering on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

Who are Context Therapeutics' major shareholders?

Context Therapeutics' top institutional shareholders include Great Point Partners LLC (9.25%), Franklin Resources Inc. (2.47%), Ally Bridge Group NY LLC (2.34%) and Geode Capital Management LLC (0.77%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit.
View institutional ownership trends.

How do I buy shares of Context Therapeutics?

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Context Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 12/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNTX
• CUSIP: N/A
• CIK: 1842952
• Web: www.contexttherapeutics.com
• Phone: 267-225-7416
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.80
• High Stock Price Target: $10.00
• Low Stock Price Target: $4.50
• Potential Upside/Downside: +566.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,960,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.76%
• Return on Assets: -55.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 36.91
• Quick Ratio: 36.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.74 per share
• Price / Book: 1.38

Miscellaneous

• Outstanding Shares: 74,998,000
• Free Float: 72,718,000
• Market Cap: $76.50 million
• Optionable: Not Optionable
• Beta: 2.00